Really interesting study this week comparing the IL17 inhibitor ixekizumab WITH the GLP1 inhibitor tirzepatide to ixekizumab alone. Raises some interesting questions about what worked here and whether or not it matters how it worked. 

Paper: https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.70134

Newsletter: http://autoimmunedevreport.com/